Home Recalls D-067-2013
Class II · Moderate risk Terminated Initiated Nov 5, 2012 (14 years ago)
Pradaxa (dabigatran etexilate), 75 mg Capsules, 60 count bottles, Rx only, Distributed by…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
Defective container; damaged bottles could allow moisture to get into the bottle and thus may impair the quality of the product
What was recalled
Pradaxa (dabigatran etexilate), 75 mg Capsules, 60 count bottles, Rx only, Distributed by Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT --- NDC 0597-0149-54
Recalling firm Boehringer Ingelheim Roxane Inc
NDC code 0597-0149-54
Origin OH, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-067-2013
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class III · Low risk Ongoing Jul 16, 2026
Reason Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
Class III · Low risk Ongoing Jul 16, 2026
Reason Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
Class III · Low risk Ongoing Jul 16, 2026
Reason Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total…
Class III · Low risk Ongoing Jun 30, 2026
Reason Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…
Class III · Low risk Ongoing Jun 30, 2026
Reason Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II…